Stuart Therapeutics, Inc. Appoints Dave LeCause as Senior Commercial Advisor - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Stuart Therapeutics, Inc. Appoints Dave LeCause as Senior Commercial Advisor

New hire to commercialize a new class of collagen-reparative therapeutics

  • September 18, 2026

  • 2 min

Share

  • 1

    Stuart Therapeutics, Inc. appointed Dave LeCause as senior commercial advisor to lead its commercial strategy.

  • 2

    LeCause will oversee the advancement of ST-100, the company's lead therapeutic candidate for dry eye disease.

  • 3

    ST-100 is anticipated to enter Phase 3b clinical trials in the first quarter of 2027.

  • 4

    LeCause previously held key roles at Allergan, including vice president and general manager of the eye care franchise.

  • 5

    Eric Schlumpf, CEO of Stuart Therapeutics, emphasized LeCause's experience in launching first-in-class therapies.

Original Source(s)

Stuart Therapeutics, Inc. Appoints Dave LeCause as Senior Commercial Advisor

  • September 18, 2026

Related Content

The prevalence and association between electronic cigarette use and dry eye symptom severity among Palestinian university students: a cross-sectional study

Dry Eye Dx and Tx: <br>Telehealth Enters the Dry Eye Arena</br>

When Vision Fluctuates, Look to the Tear Film First

Dr. Theriot discusses the differences between natural tear film and artificial tears—and why the change in moniker to "lubricating drops" is appropriate.